Latest articles
AUGUSTUS trial demonstrates favourable safety results
The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
EC approves Praluent®to reduce risk in ASCVD patients
The European Commission (EC) has approved a new indication for Praluent® (alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease...
Pharma and women’s health partnerships
The Primary Care Women’s Health Forum presents many opportunities for partnerships that improve women’s health. The Primary Care Women’s Health Forum (PCWHF) was originally created...
Popular articles
Pharma talent on show at Pf Awards 2019
The biggest names in the pharmaceutical industry came together at the Royal Lancaster London on the evening of 14 March. The largest pharmaceutical sales...
Digital partnerships in pharma and the NHS
Can pharma and the NHS equal the fast pace of change necessary to fully embrace technological innovation? Over the last few years, slowly but surely,...
AUGUSTUS trial demonstrates favourable safety results
The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Market Access in practice: do you have a strategy?
This article is a little old... but if you're interested in Market Access we have plenty of new content: July 2018 Market Access Special Edition...